🏛️ Verified NIH Record • Updated 2026-08-24

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (NCT06276491)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Xencor, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

Who can join: Review the eligibility criteria below.

Location: City of Hope — Duarte, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

  • City of Hope — Duarte, California
  • Stanford — Palo Alto, California
  • University of California — San Francisco, California
  • Moffitt Cancer Center — Tampa, Florida
  • Winship Cancer Institute, Emory University — Atlanta, Georgia
  • University of Chicago Medical Center — Chicago, Illinois
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
  • Karmanos Cancer Institute — Detroit, Michigan
  • University of Minnesota — Minneapolis, Minnesota
  • The John Theruer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
  • Icahn School of Medicine at Mount Sinai — New York, New York
  • Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York
  • The Ohio State University — Columbus, Ohio
  • OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
  • UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
  • SCRI Oncology Partners — Nashville, Tennessee
  • University of Virginia — Charlottesville, Virginia
  • AZ Groeninge — Kortrijk,
  • CHU de Liege — Liège,
  • Herlev Gentofte Hospital — Herlev,
  • NEXT Oncology - Hospital Quironsalud — Barcelona,
  • NEXT Oncology - Hospital Quironsalud — Madrid,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗